Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Boehringer Ingelheim GmbH signed a licensing agreement with Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments. The deal carries a potential value exceeding $7 billion. Terms specifying upfront payments, milestones, and royalties were not disclosed.

• Bloomberg — Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Next story